ArticleAging clinical and experimental research2025
Development and validation of a Wechat mini app-based screening tool (eR-BFAS) for early detection of Parkinson's disease.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundParkinson's disease (PD), a progressive neurodegenerative disorder, requires early detection to optimize outcomes. However, existing screening tools are often complex and not widely accessible, especially for elderly individuals.
objectiveTo develop and evaluate the reliability and validity of a WeChat Mini app-based screening tool (eR-BFAS) that combines motor symptom assessment with non-motor symptom scales for sleep disorders and hyposmia, to effectively identify early-stage PD.
methodsThe eR-BFAS was developed by integrating the Baylor Functional Assessment Screen (BFAS), Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ), and Hyposmia Rating Scale (HRS). The tool was deployed via WeChat, and participants with mild motor impairments, sleep disorders, or olfactory dysfunction completed the self-assessment. The patients' final diagnoses were followed up, and confirmatory factor analysis, internal consistency, test-retest reliability, and diagnostic performance were evaluated.
resultsA total of 132 participants completed the eR-BFAS, which comprises 24 items assessing motor symptoms, sleep disorders, and olfactory dysfunction. The tool demonstrated strong internal consistency (Cronbach's alpha = 0.875) and excellent test-retest reliability (ICC = 0.927). Confirmatory factor analysis indicated good structural validity (χ²/df = 1.573, RMSEA = 0.064, CFI = 0.927). The eR-BFAS achieved a predictive accuracy of 87.9% with an optimal cut-off score of 27 points, yielding sensitivity of 86.7% and specificity of 88.9%.
conclusionsThe eR-BFAS, integrating motor and non-motor symptom assessments, is a reliable and effective tool for screening early-stage PD. Leveraging the accessibility of WeChat, this tool has the potential to facilitate early detection and intervention in community settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.